Tigecycline susceptibility in multidrug resistant Acinetobacter isolates from Turkey

• Autorzy: Yilmaz F.F. , Tasli H. , Gul-Yurtsever S. , Buyuk A. , Hosgor-Limoncu M.
• Języki publikacji: EN

Abstrakty

EN

The present study aimed to evaluate antimicrobial activity of tigecycline against 84 multidrug resistant (MDR) Acinetobacter spp. strains by disc diffusion and E-test methods. The results of disc diffusion test were compared according to two different interpretation ways. In addition, E-test results and the disc diffusion results that interpreted by both the methods were checked for compatibility. According to the disc diffusion test, 3 strains (3.57%) were found resistant to tigecycline when considering breakpoints suggested by Food and Drug Administration (FDA). On the other hand, none of the strains was found resistant to the evaluation criteria recommended by Jones et al. (2007). Considering E-test results of tigecycline, MIC₅₀ and MIC₉₀ values of tigecycline for Acinetobacter spp. were 0.75 and 1 mg/l, respectively. Based on FDA defined breakpoints for Enterobacteriaceae, any resistant isolate was detected. In conclusion, although there are some differences in the results, tigecycline was found quite effective on Acinetobacter spp. isolates with reference to the both disc diffusion and the E-test methods.

Słowa kluczowe

EN

tigecycline; susceptibility; multidrug resistance; Acinetobacter; isolate; nosocomial infection; Turkey [geogr.]

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2013
• Tom: 62
• Numer: 3
• Opis fizyczny: p.295-298,ref.

Twórcy

autor

Yilmaz F.F.

• Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Ege University, Izmir, Turkiye

autor

Tasli H.

• Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Ege University, Izmir, Turkiye

autor

Gul-Yurtsever S.

• Izmir Katip Celebi University, Ataturk Training and Research Hospital Medical Microbiology Laboratory, Izmir, Turkiye

autor

Buyuk A.

• Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Ege University, Izmir, Turkiye

autor

Hosgor-Limoncu M.

• Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Ege University, Izmir, Turkiye

Bibliografia

• Bolmstrom A., A. Karlsson, A. Engelhardt, P. Ho, P.J. Petersen, P.A. Bradford and C.H. Jones. 2007. Validation and reproducibility assessment of tigecycline MIC determinations by etest. J. Clin. Microbiol. 45: 2474–2479.
• Clinical and Laboratory Standards Institute. 2011. Performance antimicrobial susceptibility testing, Documents: M100-S16. CLSI. Wayne, PA.
• Falagas M.E., E.A. Karveli, I.I. Siempos and K.Z. Vardakas. 2008. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol. Infect. 136: 1009–1019.
• Fraise A.P. 2006. Tigecycline: The answer to beta-lactam and fluoroquinolone resistance? J. Infect. 53: 293–300.
• Gülhan B., Ş. Nergiz, S. Meşe, T. Özekinci and S. Atmaca. 2009. Evaluation of disk diffusion zone diameters by two different breakpoints for tigecycline in Acinetobacter baumannii strains (in Turkish). ANKEM Derg. 23: 78–81.
• Hope R., T. Parsons, S. Mushtaq, D. James and D.M. Livermore. 2007. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method. J. Antimicrob. Chemother. 60: 770–774.
• Jones R.N., M.J. Ferraro, L. Barth Reler, P.C. Schreckenberger, J.M. Swenson and H.S. Sader. 2007. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J. Clin. Microbiol. 45: 227–230.
• Kulah C., G. Celebi, E. Aktas, Z. Mengeloglu, F. Comert and H. Ankarali. 2009. Unexpected tigecycline resistance among Acineto bacter baumannii Isolates: high minor error rate by E-test. J. Chemother. 21: 390–395.
• Liu J.-W., T.-N. Jang, Y.-J. Cheng, G.-J. Hsu, W. Sun, C.-T. Lu and P.-R Husueh. 2010. Comparison of the E-test and broth microdilution method for tigecycline susceptibility testing against clinical isolates of Acinetobacter baumannii from Taiwan. Int. J. Antimic. Agents. 35: 200–209.
• Manchanda V., S. Sanchaita and N.P. Singh. 2010. Multidrug resistant Acinetobacter. J. Global. Infect. Dis. 2: 291–304.
• Mendes R.E., D.J. Biedenbach, M.R.K. Alley, H.S. Sader and R.N. Jones. 2010. Potency and spectrum of activity of AN 3365 a novel boron-containing protein synthesis inhibitor tested against Enterobacteriaceae 50th ICAAC, Boston F1-1638.
• Neonakis I.K., D.A. Spandidos and E. Petinaki. 2011. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int. J. Antimic. Agents. 37: 102–109.
• Peterson L.R. 2008. A review of tigecycline-the first glycylcycline. Int. J. Antimic. Agents. 32: 215–222.
• Pillar C.M., D.C. Draghi, M.J. Dowzicky and D.F. Sahm. 2008. In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and Etest. J. Clin. Microbiol. 46: 2862–2867.
• Shakoor S., E. Khan, A. Zafar and R. Hasan. 2011. In vitro activity of tigecycline and other tetracyclines against carbapenem-resistant Acinetobacter species: report from a tertiary care centre in Karachi, Pakistan. Chemotherapy 2010. 56:184–189.
• Thamlikitkul V., S. Tiengrim and C. Tribuddharat. 2007. Comment on: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 60: 177–178.
• Wang Y.F. and M.J. Dowzicky. 2010. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the tigecycline evaluation and surveillance trial, 2004 to 2008. Diagn. Microbiol. Infect. Dis. 68: 73–79.
• Zarate M.S., G. Serruto and J. Smayevsky. 2010. The susceptibility to tigecycline of Acinetobacter spp. may vary depending on the methodology used. Int. J. Inf. Dis. 14: 351–352.